Pirnhrombin G20210A polymorphism and thrombophilia

Mayo Clinic Proceedings

Volumn 75, Issue 6, 2000, Pages 595-604

  Nguyen, Adrian ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTHROMBIN;

BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DYSFIBRINOGENEMIA; GENE MUTATION; GENE SEGREGATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GEOGRAPHIC DISTRIBUTION; HUMAN; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0034082445     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.6.595     Document Type: Review

References (62)

1. Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am. 1998; 12:1141-1166.
2. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost. 1997;78: 1-6.
3. Virchow RLK. Phlogose und Thrombose im Gefässytem. In: Gesammelte Abhandlungen zur wissenschaftliche Medicin. Frankfurt, Germany: Verlag von Meidlinger Sohn; 1856.
4. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965; 13:516-530.
5. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. / Clin Invest. 1981 ;68:1370-1373.
6. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984;64:1297-1300.
7. Bithell TC. Hereditary dysfibrinogenemia. Clin Chem. 1985;31: 509-516.
8. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood. 1995;85:330-336.
9. Faioni EM, Merati G, Peyvandi F, Bettini PM, Mannucci PM. The G1456 to T mutation in the thrombomodulin gene is not frequent in patients with venous thrombosis [letter]. Blood. 1997; 89:1467.
10. Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet. 1985;2:413-414.
11. Bertina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJ. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost. 1987;57:196-200.
12. Bienvenu T, Ankri A, Chadefaux B, Kamoun P. Plasma homocysteine assay in the exploration of thrombosis in young subjects [in French]. Presse Med. 1991;20:985-988.
13. den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995;345:882-885.
14. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48: 536-545.
15. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
17. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden. Blood. 1995;85:1504-1508.
18. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995; 73:87-93.
19. Heijboer H, Brandjes DPM, Biiller HR, Sturk A, ten Gate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323: 1512-1516.
20. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Er J Haematol. 1994;87:106112.
21. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334: 759-762.
22. Ferraresi P, Marchetti G, Legnani G, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vase Biol. 1997';17:2418-2422.
23. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997;78:1426-1429.
24. Frenkel EP, Bick RL. Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations. Semin Thromb Hemost. 1999;25:375-386.
25. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998; 79:706-708.
26. Howard TE, Marusa M, Boisza J, et al. The prothrombin gene 3'untranslated region mutation is frequently associated with factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency [letter]. Blood. 1998;91:1092.
27. Rahimy MC, Krishnamoorthy R, Ahouignan G, Laffan M, Vulliamy T. The 20210A allele of prothrombin is not found among sickle cell disease patients from West Africa [letter]. Thromb Haemost. 1998;79:444-445.
28. Lin JS, Shen MC, Tsay W. The mutation at position 20210 in the 3'untranslated region of the prothrombin gene is extremely rare in Taiwanese Chinese patients with venous thrombophilia [letter]. Thromb Haemost. 1998;80:343.
29. Isshiki I, Murata M, Watanabe R, et al. Frequencies of prothrombin 20210 G-A mutation may be different among races-studies on Japanese populations with various forms of thrombotic disorders and healthy subjects [letter]. Blood Coagul Fibrinolysis. 1998; 9:105-106.
30. Leroyer C, Mercier B, Oger E, et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost. 1998;80:49-51.
31. Souto JC, Coll I, Llobet D, et al. The prothrombin 2021OA allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost. 1998;80:366-369.
32. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G-A20210 gene variant. Ann Intern Med. 1998; 129:89-93.
33. Akar N, Misirlioglu M, Akar E, Aveu F, Yalcin A, Sozuoz A. Prothrombin gene 20210 G-A mutation in the Turkish population [letter]. AmJHematol. 1998;58:249.
34. Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 1998;92:1119-1124.
35. Ölafsson I, Hjaltadöttir S, Önundarson PT, Porarinsdottir R, Haraldsdottir V. Prevalence of factor V(Q506) and prothrombin 20210 A mutations in an apparently healthy Icelandic population and patients suffering from venous thrombosis [letter]. Thromb Haemost. 1998;79:685-686.
36. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene. BrJHaematol. 1997;98:907-909.
37. Corral J, Gonzalez-Conejero R, Lozano ML, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. BrJHaematol. 1997;99:304-307.
38. Gumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol. 1997;98:353355.
39. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost. 1999;81:733738.
40. Hillarp A, Zöller B, Svensson PJ, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78:990-992.
41. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H, DURAC Trial Study Group, Duration of Anticoagulation. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost. 1999\8\ :684-689.
42. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost. 1997;78:14301433.
43. Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost. 1999;81:861-864.
44. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 2021OA. Circulation. 1998;97:1037-1041.
45. Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost. 1998;80:878-880.
46. Franco RF, Trip MD, ten Gate H, et al. The 20210 G->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. BrJHaematol. 1999;104:50-54.
47. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999; 99:999-1004.
48. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
49. Watzke HH, Schuttrumpf J, Graf S, Huber K, Panzer S. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res. 1997;87:521-526.
50. De Stefane V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischémie disease in young patients. Blood. 1998;91:3562-3565.
51. Martinelli I, Franchi F, Akwan S, Bettini P, Merati G, Mannucci PM. The transition G to A at position 20210 in the 3'-untranslated region of the prothrombin gene is not associated with cerebral ischemia [letter]. Blood. 1997;90:3806.
52. Scott CM, Hanley JP, Ludlam CA, Stirling D. Homozygosity for a factor II polymorphism associated with thrombosis during pregnancy [abstract]. Thromb Haemost. 1997;77(suppl):770.
53. Howard TE, Marusa M, Channell C, Duncan A. A patient homozygous for a mutation in the prothrombin gene 3'-untranslated region associated with massive thrombosis. Blood Coagul Fibrinolysis. 1997;8:316-319.
54. Souto JC, Mateo J, Soria JM, et al. Homozygotes for prothrombin gene 20210 A allele in a thrombophilic family without clinical manifestations of venous thromboembolism. .Haematologica. 1999;84:627-632.
55. Morange PE, Barthet MC, Henry M, et al. A three-generation family presenting five cases of homozygosity for the 20210 G to A prothrombin variant [letter]. Thromb Haemost. 1998;80:859-860.
56. De Stefane V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
57. Alhenc-Gelas M, Le Cam-Duchez V, Emmerich J, et al. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gin mutation in thrombophilic families [letter]. Blood. 1997;90:1711.
58. De Stefano V, Chiusolo P, Paciaroni K, et al. Prevalence of the factor IIG20210A mutation in symptomatic patients with inherited thrombophilia [letter]. Thromb Haemost. 1998;80:342-343.
59. Ehrenforth S, Ludwig G, Klinke S, Krause M, Scharrer I, NowakGottl U. The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gin mutation with venous thrombophilia [letter]. Blood. 1998;91:2209-2210.
60. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging. 1999;14:55-61.
61. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.
62. Walker ID. Factor V Leiden: should all women be screened prior to commencing the contraceptive pill? Blood Rev. 1999;13:8-13.